A Study of LY3841136 in Overweight and Obese Participants
Active Not Recruiting
The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/21/2025
Locations: Fortrea Clinical Research Unit, Madison, Wisconsin
Conditions: Obesity, Overweight